Compare Repligen Corporation Common Stock (RGEN) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Twilio Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Twilio Inc trades at $268.1 (market cap $43.25B). The key difference: Twilio Inc is far larger — about 3.9× Repligen Corporation Common Stock's market cap, and Twilio Inc is more actively traded (1,616,308 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Twilio Inc for 56 Days on average.
| RGEN | TWLO | |
|---|---|---|
Market Cap | $11.14B | $43.25B |
Volume | 1,259,263 | 1,616,308 |
Sector | Health | Technology |
52-Week High | $194.57 | $301.27 |
52-Week Low | $102.87 | $106.23 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $11.02B | $41.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Twilio stock trades at $271.12, down 4.08% today, amid mixed signals. The technical outlook is bullish based on moving averages, with key support at $268. Fundamentally, revenue grew to $5.07B in 2025, with net income turning positive at $33.83M after years of losses. Recent news highlights its upcoming addition to the S&P 500 index effective October 6, 2026, a positive catalyst for institutional interest.
The outlook is cautiously optimistic given strong analyst support (76.9% buy ratings) and a consensus price target of $257.59, though the stock trades above this level. Risks include high valuation multiples (P/E 38.89) and competitive pressures in customer engagement software. Earnings beats in recent quarters support growth momentum, but investors should weigh rich valuations against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
